Introduction
============

Canakinumab (CAN), a selective, human, anti- interleukin-1β monoclonal antibody, has been shown to be efficacious in the treatment of SJIA (Ruperto et al. N Engl J Med 2012).

Objectives
==========

To explore baseline demographics and clinical characteristics that are most predictive of response to CAN in CAN-naïve SJIA patients during the initial 12 weeks of therapy.

Methods
=======

Data from 3 trials were pooled for this analysis. CAN-naïve patients (pts; n=178) aged 2--19 years with active SJIA were enrolled and received sc CAN 4 mg/kg/month; Predictors of response (according to aACR\* 30, 70, and Inactive Disease \[ID\]) at Days (D) 15, 29, 57 and 85 were explored using univariate and multivariate logistic regression analyses. The candidate predictors (categorical variables) of CAN-response considered were: Age group, Gender, Prior NSAIDS (no/yes), Prior MTX(no/yes), Steroids (0, \>0 -- ≤0.4;\> 0.4), Number of Active Joints(≤10, 11-≤20, \>20) and Joints with Limitation of Motion (≤10, 11-≤20,\>20), CRP (elevated/normal) at baseline and at D15. All candidate predictors with p\<0.1 in univariate analyses were included in the multivariate analysis. \*ACR response plus absence of fever.

Results
=======

By week 2 there was substantial clinical benefit with 102 pts (57%) and 36 pts (20%) achieving aACR70 and ID, respectively; by week 12, 108 pts (61%) had aACR70 and 50 pts (28%) ID. The multivariate analysis indicated that normal CRP at D15 is the only predictor significant (all p \< 0.05) for ID at all time-points (Table [1](#T1){ref-type="table"}).

###### 

Inactive Disease - Multivariate logistic regression analysis on 12-week data

  Variable\*, Odds Ratio (95% CI)                    Day 15                  Day 29                   Day 57                     Day 85
  -------------------------------------------------- ----------------------- ------------------------ -------------------------- --------------------------
  **CRP at Day 15 (elevated vs normal)**             **0.20 (0.07, 0.55)**   **0.14 (0.04, 0.41)**    **0.26 (0.10, 0.66)**      **0.31 (0.12, 0.82)**
                                                                                                                                 
  **Number of active joints (11-≤20 vs. ≤10)**       0.22 (0.03, 1.66)       0.55 (0.09, 3.41)        **0.17 (0.031, 0.97)**     0.37 (0.06, 2.10)
                                                                                                                                 
  **Number of active joints (≤10 vs. \>20)**         2.56 (0.12, 55.39)      1.53 (0.06, 37.44)       **16.10 (1.00, 258.12)**   **25.41 (1.60, 404.61)**
                                                                                                                                 
  **Prior NSAID treatment (no vs. yes)**             2.01 (0.71, 5.71)       **9.33 (2.44, 35.68)**   **3.10 (1.03, 9.31)**      **5.31 (1.66, 17.05)**
                                                                                                                                 
  **Steroid Level (0 vs. \>0.4 mg/kg/day)**          5.48 (0.97, 31.01)      **8.89 (1.26, 62.64)**   2.98 (0.51, 17.46)         **11.16 (1.72, 72.34)**
                                                                                                                                 
  **Steroid Level (\>0.4 vs. \>0-≤0.4 mg/kg/day)**   0.32 (0.08, 1.29)       0.41 (0.09, 1.82)        0.81 (0.25, 2.60)          **0.13 (0.03, 0.57)**
                                                                                                                                 
  **Prior MTX treatment (no vs. yes)**               1.94 (0.75, 5.00)       2.78 (0.93, 8.33)        **2.79 (1.04, 7.51)**      1.77 (0.65, 4.83)
                                                                                                                                 
  **Prior anti-TNFs treatment (no vs. yes)**         1.83 (0.52, 6.49)       3.62 (0.77, 17.00)       2.01 (0.63, 6.38)          **3.64 (1.04, 12.77)**

Values in bold are significant; \*Significant in at least one time point

Conclusion
==========

This exploratory analysis suggests that CAN-naïve patients with normal CRP (i.e. ≤10 mg/l) at Day 15, lower baseline steroid doses, low number of active joints, no prior anti-TNF or prior NSAID use are those most likely to achieve inactive disease up to 12 weeks.
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